Does the media prefer ANIK or ANVS?

In the previous week, Anika Therapeutics had 3 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Anika Therapeutics and 3 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 1.11 beat Annovis Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LXRX or ANIK?

In the previous week, Lexicon Pharmaceuticals had 15 more articles in the media than Anika Therapeutics. MarketBeat recorded 21 mentions for Lexicon Pharmaceuticals and 6 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.11 beat Lexicon Pharmaceuticals' score of 0.07 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANIK or CGEM?

In the previous week, Anika Therapeutics and Anika Therapeutics both had 6 articles in the media. Anika Therapeutics' average media sentiment score of 1.11 beat Cullinan Therapeutics' score of 0.16 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OLMA or ANIK?

In the previous week, Anika Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Anika Therapeutics and 4 mentions for Olema Pharmaceuticals. Anika Therapeutics' average media sentiment score of 1.11 beat Olema Pharmaceuticals' score of 0.58 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JBIO or ANIK?

In the previous week, Anika Therapeutics had 3 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Anika Therapeutics and 3 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.12 beat Anika Therapeutics' score of 1.11 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anika Therapeutics (ANIK) Competitors

$20.84 -0.59 (-2.73%)

As of 02:13 PM Eastern

Compare

ANIK vs. ANVS, LXRX, CGEM, OLMA, and JBIO

Should you buy Anika Therapeutics stock or one of its competitors? MarketBeat compares Anika Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anika Therapeutics include Annovis Bio (ANVS), Lexicon Pharmaceuticals (LXRX), Cullinan Therapeutics (CGEM), Olema Pharmaceuticals (OLMA), and Jade Biosciences (JBIO). These companies are all part of the "biotechnology" industry.

How does Anika Therapeutics compare to Annovis Bio?

Anika Therapeutics (NASDAQ:ANIK) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anika Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 0.79%. Annovis Bio has a consensus price target of $11.67, indicating a potential upside of 525.56%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Annovis Bio	N/A	-318.08%	-215.47%

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Anika Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

In the previous week, Anika Therapeutics had 3 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Anika Therapeutics and 3 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 1.11 beat Annovis Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Anika Therapeutics beats Annovis Bio on 9 of the 14 factors compared between the two stocks.

How does Anika Therapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Anika Therapeutics has a net margin of -3.14% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Anika Therapeutics' return on equity of 0.20% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Anika Therapeutics	-3.14%	0.20%	0.15%

Anika Therapeutics has higher revenue and earnings than Lexicon Pharmaceuticals. Anika Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	21.85	-$50.34M	-$0.15	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, suggesting a potential upside of 86.09%. Anika Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 0.79%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Lexicon Pharmaceuticals had 15 more articles in the media than Anika Therapeutics. MarketBeat recorded 21 mentions for Lexicon Pharmaceuticals and 6 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.11 beat Lexicon Pharmaceuticals' score of 0.07 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Anika Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Cullinan Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Anika Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Anika Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 0.79%. Cullinan Therapeutics has a consensus target price of $32.14, indicating a potential upside of 79.42%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Anika Therapeutics and Anika Therapeutics both had 6 articles in the media. Anika Therapeutics' average media sentiment score of 1.11 beat Cullinan Therapeutics' score of 0.16 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Anika Therapeutics beats Cullinan Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Anika Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Anika Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Anika Therapeutics and 4 mentions for Olema Pharmaceuticals. Anika Therapeutics' average media sentiment score of 1.11 beat Olema Pharmaceuticals' score of 0.58 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Anika Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Anika Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Olema Pharmaceuticals has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Anika Therapeutics	-3.14%	0.20%	0.15%

Olema Pharmaceuticals presently has a consensus target price of $44.10, suggesting a potential upside of 269.28%. Anika Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 0.79%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Anika Therapeutics beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

91.5% of Anika Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Jade Biosciences has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Anika Therapeutics	-3.14%	0.20%	0.15%

Jade Biosciences presently has a consensus price target of $51.57, indicating a potential upside of 138.66%. Anika Therapeutics has a consensus price target of $21.00, indicating a potential upside of 0.79%. Given Jade Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Jade Biosciences is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Anika Therapeutics had 3 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Anika Therapeutics and 3 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.12 beat Anika Therapeutics' score of 1.11 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Anika Therapeutics has higher revenue and earnings than Jade Biosciences. Anika Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

Summary

Jade Biosciences beats Anika Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Anika Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIK vs. The Competition

Export

Metric	Anika Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$277.63M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-76.83	9.08	269.95	24.78
Price / Sales	2.31	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.09	17.64	11.25	6.43
Net Income	-$10.88M	-$13.25M	$3.45B	$347.27M
7 Day Performance	0.46%	5.21%	3.49%	2.53%
1 Month Performance	33.56%	-1.94%	-0.66%	-1.03%
1 Year Performance	156.91%	60.76%	77.20%	23.28%

Anika Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIK Anika Therapeutics	3.4535 of 5 stars	$20.84 -2.7%	$21.00 +0.8%	+164.1%	$277.63M	$120.65M	N/A	300	Positive News Gap Up
ANVS Annovis Bio	2.6833 of 5 stars	$1.72 -1.5%	$11.67 +576.7%	-27.1%	$60.63M	N/A	N/A	3	News Coverage Positive News Upcoming Earnings
LXRX Lexicon Pharmaceuticals	1.5065 of 5 stars	$2.33 +0.9%	$4.55 +95.3%	+128.7%	$1.03B	$49.80M	N/A	140	Earnings Report Analyst Downgrade Analyst Revision
CGEM Cullinan Therapeutics	2.6721 of 5 stars	$16.25 -1.5%	$32.14 +97.8%	+142.9%	$1.01B	N/A	N/A	30	Earnings Report
OLMA Olema Pharmaceuticals	1.9899 of 5 stars	$11.28 -1.5%	$44.10 +291.0%	+159.7%	$1.00B	N/A	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIK) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, LXRX, CGEM, OLMA, and JBIO

How does Anika Therapeutics compare to Annovis Bio?

Summary

How does Anika Therapeutics compare to Lexicon Pharmaceuticals?

Summary

How does Anika Therapeutics compare to Cullinan Therapeutics?

Summary

How does Anika Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Anika Therapeutics compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, LXRX, CGEM, OLMA, and JBIO

How does Anika Therapeutics compare to Annovis Bio?

Do institutionals & insiders believe in ANIK or ANVS?

Do analysts prefer ANIK or ANVS?

Is ANIK or ANVS more profitable?

Which has preferable valuation and earnings, ANIK or ANVS?

Which has more risk & volatility, ANIK or ANVS?

Does the media prefer ANIK or ANVS?

Summary

How does Anika Therapeutics compare to Lexicon Pharmaceuticals?

Do institutionals and insiders hold more shares of LXRX or ANIK?

Which has more risk and volatility, LXRX or ANIK?

Is LXRX or ANIK more profitable?

Which has higher valuation and earnings, LXRX or ANIK?

Do analysts prefer LXRX or ANIK?

Does the media refer more to LXRX or ANIK?

Summary

How does Anika Therapeutics compare to Cullinan Therapeutics?

Which has more volatility & risk, ANIK or CGEM?

Do institutionals & insiders have more ownership in ANIK or CGEM?

Is ANIK or CGEM more profitable?

Which has better valuation & earnings, ANIK or CGEM?

Do analysts recommend ANIK or CGEM?

Does the media prefer ANIK or CGEM?

Summary

How does Anika Therapeutics compare to Olema Pharmaceuticals?

Does the media refer more to OLMA or ANIK?

Which has more risk & volatility, OLMA or ANIK?

Which has better earnings & valuation, OLMA or ANIK?

Do insiders and institutionals hold more shares of OLMA or ANIK?

Is OLMA or ANIK more profitable?

Do analysts recommend OLMA or ANIK?

Summary

How does Anika Therapeutics compare to Jade Biosciences?

Do insiders & institutionals have more ownership in JBIO or ANIK?

Is JBIO or ANIK more profitable?

Do analysts recommend JBIO or ANIK?

Does the media prefer JBIO or ANIK?

Which has more risk and volatility, JBIO or ANIK?

Which has stronger valuation & earnings, JBIO or ANIK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools